On December 12, 2024, the tenth batch of centralized procurement of drugs organized by the State produced the results of the proposed selection. Collection is not a new drug, and new drugs are not collected. Collective mining reflects the market competitiveness of enterprises and products more by exchanging quantity for price.
There are 62 kinds of drugs successfully purchased in this collection, all of which have passed the patent period, have been produced by a number of enterprises, and have full competition, covering the fields of hypertension, diabetes, cancer, cardiovascular and cerebrovascular diseases, infection, and mental diseases. Pharmaceutical companies actively participated in this collection, and 385 products from 234 companies were eligible for the proposed selection, and the selected drugs were all high-quality drugs that passed the consistency evaluation of quality and efficacy.
On the one hand, this collection will effectively improve the quality of medication for patients, and promote the widespread replacement of unevaluated drugs by drugs that have passed the consistency evaluation of quality and efficacy; On the other hand, the drug structure will be improved, and drugs with different mechanisms of action or better efficacy and more convenient use in the same treatment field will be widely entered into the clinic, comprehensively promoting the quality and upgrading of drug use for patients.
For example, Doxorubicin hydrochloride liposome injection, a first-line drug for breast cancer, can effectively reduce adverse drug reactions and significantly improve drug safety compared with ordinary doxorubicin products. For example, Marxitentan tablet is a new generation of drugs to treat the rare disease pulmonary hypertension, which will provide more treatment options for patients.
Another example is the inclusion of several compound preparations such as sitagliptin and metformin tablets in this collection. Patients can take sitagliptin and metformin two mainstream hypoglycemic drugs once taking medication, which can play a synergistic role, avoid the problems of missing or mistaking caused by taking unilateral drugs separately, and increase medication compliance and convenience.
This collection also showed the characteristics of stable expectations, stable supply and promoting reform. First, stable expectations, the annual procurement demand of medical institutions in the country reached 9 billion pieces (branches), and stabilized the production capacity and supply chain expectations of enterprises in the next three years in a “with volume” way.
The second is stable supply, with an average of more than 6 enterprises winning bids for each drug, promoting a more stable and diversified supply. Actively promote the stable supply and price of emergency medicine and shortage medicine, while clarifying the supply expectation of enterprises through “carrying quantity”, implement the supply mode of “one business owner supply and two enterprises supply” in each province, and improve the resilience of clinical supply.
The third is to promote reform, the winning enterprises do not need to invest excessive marketing costs, can directly sell drugs to the national medical institutions, further optimize the circulation link, purify the industry ecology, and promote the construction of a unified national market.
Since 2018, the National Medical Insurance Bureau has organized 10 batches of state-organized drug collection together with relevant departments, and successfully purchased 435 kinds of drugs. Through centralized procurement, a large number of classic “old drugs” that have passed the patent period are all supplied to the country by enterprises that have passed the consistency evaluation of quality and efficacy.
While reducing the cost burden of “old drugs” for the masses, freeing up cost space to provide conditions for supporting the inclusion of new drugs in medical insurance, seven consecutive rounds of adjustment of the national medical insurance drug catalog has accumulated negotiations to include 530 new drugs, constantly improving and optimizing the structure of mass drug use, and promoting the quality and upgrading of the pharmaceutical industry.
The selected results of this collection will be officially released after publicity. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country will use the selected products in April 2025.
At the same time, the medical insurance department is vigorously promoting the collection of drugs into grass-roots medical institutions, into private medical institutions, and into pharmacies, so that the masses can more easily use high-quality and affordable products.
Promote the unified settlement of medical institutions and collection selected enterprises on the medical insurance information platform, explore and promote the direct settlement of medical insurance funds and pharmaceutical enterprises on this basis, improve the efficiency of drug procurement funds, and benefit the majority of pharmaceutical enterprises.
Related topics
